Daiichi Sankyo discovered new patritumab deruxtecan to treat patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer (NSCLC).
Patritumab deruxtecan (HER3-DXd), is the firt irst-in-class HER3 directed antibody drug conjugate (ADC), applicable with third-generation tyrosine kinase inhibitor (TKI) and platinum-based therapies on or after treatment.
Patritumab deruxtecan the new treatment improves the patients surving with TKI-resistant, EGFR-mutated non-small cell lung cancer, and therby overcomes resistance.
Patritumab deruxtecan (HER3-DXd) is a monoclonal antibody attached to a topoisomerase I inhibitor payload (an exatecan derivative, DXd) via a stable tetrapeptide-based cleavable linker. It is being evaluated in a comprehensive development program among various cancers both as monotherapy and in combination with other anticancer treatments. Moreover, patritumab deruxtecan an investigational medicine is not approved in any country for medical use.
Lung cancer one of the most common type of cancer increases the world’s mortality rates to 80 to 85 percent consisting of NSCLC. In 2020, it is estimated that new lung cancer cases raised to 2.2 million and 1.8 million deaths. In among 50 percent of patients though NSCLC is diagnosed at an advanced stage have resulted in poor outcomes after each line of subsequent therapy.
